Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

cessful NDA filing and furthering our discussions with potential collaboration partners."

Based upon the discussions with FDA, Palatin intends to finalize the protocols for the pivotal Phase 3 clinical studies and start screening patients later this year.

Quarter Ended March 31, 2013 Financial Results
For the three months ended March 31, 2013, Palatin reported a net loss of $4.0 million, or $(0.04) per basic and diluted share, compared to a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the same period in 2012. 

The decrease in net loss for the quarter ended March 31, 2013, compared to the same period last fiscal year, is attributable to a decrease in operating expenses primarily related to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. 

Revenue
Palatin did not recognize any revenues for the quarter ended March 31, 2013, compared to $23,996 for the quarter ended March 31, 2012.  Revenue consists of contract revenue under our collaboration agreement with AstraZeneca.

Costs and Expenses
Total operating expenses for the quarter ended March 31, 2013 were $4.0 million compared to $6.1 million for the comparable quarter of 2012.  The decrease in operating expenses for the quarter was primarily due to Palatin's Phase 2B clinical trial with bremelanotide for FSD and secondarily as a result of closing our research laboratory operations in connection with the lease expiration of the laboratory facilities in July 2012.

Cash Position
As of March 31, 2013, Palatin had cash and cash equivalents of $23.5 million, $6.0 million in short term investments and current liabilities of $2.7 million.  Cash and cash equivalents as of June 30, 2012 were $3.8 million with current liabilities of $3.5 million. 

Palatin believes that its existing capital resources will be adequate to fund its currently planned opera
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 In an ... the UPMC Center for Health Security review the clinical ... can be used as bioweapons. The article, "Clinical Management ... today on the website of the New England ... Adalja, Eric Toner , and Tom Inglesby—review the ...
(Date:3/4/2015)... 2015  Brooklyn residents now have a new place ... and injuries. Nunzio Saulle , M.D., a board-certified ... his NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 5, 2015. Health Plus Management, LLC is managing the ... 1178 Flatbush Avenue. This new PM&R practice will treat ...
(Date:3/4/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... Cambridge, Mass. -- May 29, 2008 -- With the aid ... Applied Sciences (SEAS) have whipped up, for the first time, ... a year from batches of foam made from a ... appears in the May 30 issue of the journal Science. ...
... Bluestar Silicones will,debut its market leading soft silicone ... East, June 3-5, in New York City., ... feature its healthcare,grade Silbione(R) brand low durometer liquid ... advantages of the Silbione(R),30- to 70-ShA LSR product ...
... Mass., May 29 Haemonetics,Corporation and Octapharma ... multi-year,supply contract appointing Haemonetics as Octapharma,s preferred ... States. Under the agreement,Octapharma will use Haemonetics, ... its U.S. plasma collection centers. Plasma is ...
Cached Biology Technology:Engineers whip up the first long-lived nanoscale bubbles 2Bluestar Silicones Debuts New Soft Elastomers at Medical Device & Manufacturing East Expo 2Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract 2
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial ... billing in the Health and Fitness Industry, today ... as to MYiCLUBonline.  The latest upgrade includes advances ... inclusion of cardless check-in via Identity One fingerprint ... first time through interactive displays at the International ...
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... convey vital medical information, but the sight of a needle ... developed by a team of researchers in Israel, however, can ... in real-time, simply by shining a light through the skin. ... to provide high-resolution images of blood coursing through our veins ...
... differences in bacterial colonization of the infant gut in formula-fed ... genes involved in the infant,s immune system. The study, ... access journal Genome Biology , is an Editor,s Pick. ... Texas A&M University, Miami University, and University of Arkansas scientists. ...
... of scientists from the National University of Singapore,s (NUS) Department ... drug-led compound a compound that is undergoing preclinical trials ... energy and stop them from growing into a tumour. This ... first time a research group has provided evidence showing how ...
Cached Biology News:New microscope uses rainbow of light to image the flow of individual blood cells 2New microscope uses rainbow of light to image the flow of individual blood cells 3Breast-fed babies' gut microbes contribute to healthy immune systems 2Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2
... With 36 mg/L sodium pyruvate, 50 mg/L ... mg/L glucose, calcium chloride, and magnesium chloride. ... (BSS) in tissue culture is generally attributed ... 1885, Sydney Ringer developed a solution of ...
... is a dramatic breakthrough in accurate, small-volume bulk ... resolution, the micro 1 has unique advantages not ... micro 1 never needs re-calibration as do other ... on an LCD Display , Graphical Row Selection ...
... Rabbit polyclonal to Rad51 ( ... Antigen: Synthetic ... to N terminal amino acids 15-29 ... Entrez Gene ID: 5888 ...
... High performance agitation and temperature control for ... four wells independently and is suitable for ... L working volume. Its temperature ranges from ... Each well is equipped with an individual ...
Biology Products: